cagrilintide 5mg (ca-5)

As of April 2026, Cagrilintide is one of the most talked-about molecules in the peptide industry. Developed by Novo Nordisk, it represents a departure from the "GLP-1 only" mindset.

Unlike Semaglutide or Tirzepatide, Cagrilintide is a long-acting amylin analogue. In your research or business intro, you would focus on its role as the "synergy partner."

1. The Mechanism: Amylin vs. GLP-1

Cagrilintide mimics amylin, a hormone co-secreted with insulin. While GLP-1 focus on the gut and slow digestion, amylin works primarily in the brain (the area postrema and hypothalamus) to trigger satiation (feeling full).

• Glucagon Suppression: It helps lower blood sugar by preventing the liver from releasing too much sugar.

• Satiety: Research shows it provides a different "fullness" sensation than GLP-1, which is why it's almost always studied in combination.

2. "CagriSema": The 2026 Powerhouse

The biggest headline in early 2026 is CagriSema—a fixed-dose combination of Cagrilintide (2.4mg) and Semaglutide (2.4mg).

• Clinical Trial Results (Feb 2026): Phase 3 results (REIMAGINE 2) showed that this combo achieved 14.2% weight loss in Type 2 Diabetics, significantly outperforming Ozempic alone.

• Obesity Results: Earlier data from the REDEFINE trials showed weight loss reaching 22.7% to 23%, putting it in direct competition with Tirzepatide (Zepbound).

3. Research Peptide Profile

For the research community, Cagrilintide is considered a specialized tool for studying "multi-receptor" weight loss.

• The "Stack": In laboratory settings, researchers often "stack" Cagrilintide with Semaglutide to observe the additive effect of dual-hormone signaling.

• Dosing (Research Standards): Typical research vials are 5mg. Because it has a long half-life, it is designed for once-weekly administration in research models.

• Side Effects: Research indicates that the combination can lead to more gastrointestinal events (nausea) than single peptides, but it avoids the "heart rate" increases seen with Retatrutide.

Comparison: The 2026 "Big Three"